Last updated on December 2018

A 24-week multicenter, randomized, double-blind, parallel-group study comparing the efficacy and safety of ixekizumab to guselkumab in patients with moderate-to-severe plaque psoriasis.


Brief description of study

The purpose of this study is to compare the efficacy and safety of ixekizumab to guselkumab in participants with moderate-to-severe plaque psoriasis.

 

Clinical Study Identifier: TX217786

Contact Investigators or Research Sites near you

Start Over

Dermatology Physicians of Connecticut

Shelton, Connecticut United States
7.12miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.